SAFETY DATA SHEET

Raltegravir / Lamivudine Formulation

Version 3.7 Revision Date: 09/13/2019 SDS Number: 184749-00010 Date of last issue: 24.04.2019

Date of first issue: 17.06.2015

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Raltegravir / Lamivudine Formulation

Manufacturer or supplier’s details

Company : MSD

Address : 50 Tuas West Drive

Singapore - Singapore 638408

Telephone : 908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

GHS Classification

Serious eye damage/eye irritation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure : Category 3

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood)

GHS label elements

Hazard pictograms :  

Signal word : Danger

Hazard statements : H318 Causes serious eye damage.

H335 May cause respiratory irritation.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.
SAFETY DATA SHEET

Raltegravir / Lamivudine Formulation

P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/protective clothing/eye protection/face protection.

Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
<td></td>
</tr>
<tr>
<td>Chemical name</td>
<td>CAS-No.</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>871038-72-1</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>134678-17-4</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
SAFETY DATA SHEET

Raltegravir / Lamivudine Formulation

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Fluorine compounds
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Do not get in eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitizers.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labelled containers.
- Store locked up.
- Keep tightly closed.
- Keep in a cool, well-ventilated place.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters
Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis  
--- | --- | --- | --- | ---  
Raltegravir | 871038-72-1 | TWA | 1,000 µg/m³ | Internal  
Lamivudine | 134678-17-4 | TWA | 150 µg/m³ (OEB 2) | Internal  
Cellulose | 9004-34-6 | PEL (long term) | 10 mg/m³ | SG OEL  
 |  | TWA | 10 mg/m³ |  
Magnesium stearate | 557-04-0 | PEL (long term) | 10 mg/m³ | SG OEL  
 |  | TWA (Inhalable fraction) | 10 mg/m³ | ACGIH  
 |  | TWA (Respirable fraction) | 3 mg/m³ | ACGIH  

**Engineering measures**: Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- **Filter type**: Particulates type
- **Hand protection**: Chemical-resistant gloves

**Remarks**: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection**: Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear: Face-shield

**Skin and body protection**: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Hygiene measures**: If exposure to chemical is likely during typical use, provide
eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder
Colour : green
Odour : No data available
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
SAFETY DATA SHEET

Raltegravir / Lamivudine Formulation

Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Conditions to avoid:
- Heat, flames and sparks.
- Avoid dust formation.

Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Not classified based on available information.

Components:

Raltegravir:
Acute oral toxicity: LD50 (Mouse, male and female): > 2,000 mg/kg

Lamivudine:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): 4,000 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration):
LD50 (Rat): > 2,000 mg/kg
Application Route: Intravenous

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity:
LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
**Magnesium stearate:**
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
   Method: OECD Test Guideline 423
   Assessment: The substance or mixture has no acute oral toxicity
   Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
   Remarks: Based on data from similar materials

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Raltegravir:**
Species: Rabbit
Result: No skin irritation

**Lamivudine:**
Species: Rabbit
Result: Mild skin irritation

**Magnesium stearate:**
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

**Serious eye damage/eye irritation**
Causes serious eye damage.

**Components:**

**Raltegravir:**
Species: Bovine cornea
Result: Severe irritation

**Lamivudine:**
Species: Rabbit
Result: No eye irritation

**Magnesium stearate:**
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials
### Respiratory or skin sensitisation

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

### Components:

#### Raltegravir:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Local lymph node assay (LLNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

#### Lamivudine:

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Dermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>

#### Magnesium stearate:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximisation Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure routes</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 406</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

#### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Raltegravir:

**Genotoxicity in vitro**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>reverse mutation assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Alkaline elution assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test system</td>
<td>rat hepatocytes</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Chromosomal aberration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>OECD Test Guideline 473</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Genotoxicity in vivo**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>In vivo micronucleus test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Chromosomal aberration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>OECD Test Guideline 475</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>
# SAFETY DATA SHEET

## Raltegravir / Lamivudine Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7</td>
<td>09/13/2019</td>
<td>184749-00010</td>
<td>24.04.2019</td>
<td>17.06.2015</td>
</tr>
</tbody>
</table>

### Lamivudine:

**Genotoxicity in vitro**

- **Test Type**: Bacterial reverse mutation assay (AMES)
  - **Result**: negative

- **Test Type**: Mouse Lymphoma
  - **Result**: equivocal

**Genotoxicity in vivo**

- **Test Type**: Micronucleus test
  - **Species**: Rat
  - **Application Route**: Oral
  - **Result**: negative

  - **Test Type**: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
    - **Species**: Rat
    - **Result**: negative

### Cellulose:

**Genotoxicity in vitro**

- **Test Type**: Bacterial reverse mutation assay (AMES)
  - **Result**: negative

- **Test Type**: In vitro mammalian cell gene mutation test
  - **Result**: negative

**Genotoxicity in vivo**

- **Test Type**: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - **Species**: Mouse
  - **Application Route**: Ingestion
  - **Result**: negative

### Magnesium stearate:

**Genotoxicity in vitro**

- **Test Type**: In vitro mammalian cell gene mutation test
  - **Result**: negative
  - **Remarks**: Based on data from similar materials

  - **Test Type**: Chromosome aberration test in vitro
    - **Method**: OECD Test Guideline 473
    - **Result**: negative
    - **Remarks**: Based on data from similar materials

  - **Test Type**: Bacterial reverse mutation assay (AMES)
    - **Result**: negative
    - **Remarks**: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### Raltegravir:

- **Species**: Mouse, male and female
- **Exposure time**: 104 weeks
Result : negative

**Lamivudine:**
Species : Rat
Exposure time : 2 Years
Result : negative

Species : Mouse
Exposure time : 2 Years
Result : negative

**Cellulose:**
Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

**Reproductive toxicity**
Suspected of damaging the unborn child.

**Components:**

**Raltegravir:**
Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: 600 mg/kg body weight
Result: negative

Effects on foetal development : Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: >= 600 mg/kg body weight
Teratogenicity: LOAEL F1: 300 mg/kg body weight
Symptoms: Skeletal malformations
Result: positive

Species: Rabbit
General Toxicity Maternal: NOAEL: >= 1,000 mg/kg body weight
Teratogenicity: NOAEL: >= 1,000 mg/kg body weight
Result: negative

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**Lamivudine:**
Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 900 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.
Effects on foetal development:

- **Species**: Rabbit  
  **Application Route**: Oral  
  **Symptoms**: Preimplantation loss, Skeletal malformations  
  **Result**: Embryotoxic effects and adverse effects on the offspring were detected.

- **Species**: Rat  
  **Application Route**: Oral  
  **Developmental Toxicity**: LOAEL: 45 mg/kg body weight  
  **Symptoms**: Effects on foetal development  
  **Result**: positive

Reproductive toxicity - Assessment:

- Some evidence of adverse effects on development, based on animal experiments.

**Cellulose:**

- **Effects on fertility**: Test Type: One-generation reproduction toxicity study  
  **Species**: Rat  
  **Application Route**: Ingestion  
  **Result**: negative

- **Effects on foetal development**: Test Type: Fertility/early embryonic development  
  **Species**: Rat  
  **Application Route**: Ingestion  
  **Result**: negative

**Magnesium stearate:**

- **Effects on fertility**: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
  **Species**: Rat  
  **Application Route**: Ingestion  
  **Method**: OECD Test Guideline 422  
  **Result**: negative  
  **Remarks**: Based on data from similar materials

- **Effects on foetal development**: Test Type: Embryo-foetal development  
  **Species**: Rat  
  **Application Route**: Ingestion  
  **Result**: negative  
  **Remarks**: Based on data from similar materials

STOT - single exposure

May cause respiratory irritation.

**Components:**

**Raltegravir:**

- **Exposure routes**: Inhalation  
- **Target Organs**: Respiratory Tract  
- **Assessment**: May cause respiratory irritation.
STOT - repeated exposure
May cause damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Components:

Lamivudine:
Exposure routes: Ingestion
Target Organs: Blood
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Raltegravir:
Species: Dog
NOAEL: 90 mg/kg
Application Route: Oral
Exposure time: 371 d
Symptoms: Vomiting

Species: Rat
NOAEL: 30 mg/kg
LOAEL: 120 mg/kg
Application Route: Oral
Exposure time: 189 d
Target Organs: Stomach

Species: Mouse
NOAEL: 50 mg/kg
LOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Stomach

Species: Rat
NOAEL: 50 mg/kg
LOAEL: 200 mg/kg
Application Route: Oral
Exposure time: 8 Weeks
Target Organs: Stomach

Lamivudine:
Species: Rat
NOAEL: 425 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Blood
Symptoms: Gastrointestinal discomfort, Breathing difficulties, Fatality
Remarks: Significant toxicity observed in testing

Species: Dog
SAFETY DATA SHEET

Raltegravir / Lamivudine Formulation

Version: 3.7
Revision Date: 09/13/2019
SDS Number: 184749-00010
Date of last issue: 24.04.2019
Date of first issue: 17.06.2015

LOAEL: 90 mg/kg
Application Route: Oral
Exposure time: 12 Months
Target Organs: Blood, spleen, Liver
Symptoms: Salivation, Diarrhoea, Changes in the blood count, Liver disorders, Gastrointestinal disturbance

Species: Mouse
NOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 1 Months
Target Organs: Blood

Cellulose:
Species: Rat
NOAEL: >= 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Magnesium stearate:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Raltegravir:
Ingestion: Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

Lamivudine:
Ingestion: Symptoms: Headache, Fatigue, Respiratory disorders, Diarrhoea, Cough

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Raltegravir:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100
mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 9.3 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 9.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Lamivudine:

Toxicity to fish:
LC50 (Pimephales promelas (fathead minnow)): > 97.7 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): > 96.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 96.9 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
**SAFETY DATA SHEET**

**Raltegravir / Lamivudine Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7</td>
<td>09/13/2019</td>
<td>184749-00010</td>
<td>24.04.2019</td>
<td>17.06.2015</td>
</tr>
</tbody>
</table>

### Cellulose:
- **Toxicity to fish**
  - LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  - Exposure time: 48 h
  - Remarks: Based on data from similar materials

### Magnesium stearate:
- **Toxicity to fish**
  - LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
  - Exposure time: 48 h
  - Method: DIN 38412
  - Remarks: Based on data from similar materials

- **Toxicity to daphnia and other aquatic invertebrates**
  - EL50 (Daphnia magna (Water flea)): > 1 mg/l
  - Exposure time: 47 h
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility

- **Toxicity to algae/aquatic plants**
  - EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility

  **NOELR** (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  - Exposure time: 72 h
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials

- **Toxicity to microorganisms**
  - EC10 (Pseudomonas putida): > 100 mg/l
  - Exposure time: 16 h
  - Method: OECD Test Guideline 111
  - Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

**Raltegravir**
- **Biodegradability**
  - Result: rapidly degradable
  - Biodegradation: 50 %
  - Exposure time: 9 d
  - Method: OECD Test Guideline 302B

- **Stability in water**
  - Hydrolysis: < 10 % (5 d)
  - Method: OECD Test Guideline 111

**Lamivudine**
- **Biodegradability**
  - Result: Not readily biodegradable.
Biodegradation: 4 %
Exposure time: 28 d

Cellulose:
Biodegradability : Result: Readily biodegradable.

Magnesium stearate:
Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Raltegravir:
Partition coefficient: n-octanol/water : log Pow: -0.328

Lamivudine:
Partition coefficient: n-octanol/water : log Pow: -1.44

Magnesium stearate:
Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Lamivudine:
Distribution among environmental compartments : log Koc: 2.03

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations : Not applicable

Fire Safety (Petroleum and Flammable Materials) Regulations : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : dd.mm.yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)

SG OEL : Singapore. Workplace Safety and Health Act - First Schedule Permissible Exposure Limits of Toxic Substances

ACGIH / TWA : 8-hour, time-weighted average

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.